Category - Developments

Developments

Praxis reports positive topline results from study of relutrigine in developmental epilepsies

Praxis Precision Medicines (NASDAQ:PRAX) has announced positive topline results from its EMBOLD Phase II proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy...

September 3, 2024

Developments

Nuvectis receives FDA orphan drug designation for NXP800 targeting cancer

The FDA granted orphan drug designation (ODD) to Nuvectis Pharma’s (NASDAQ:NVCT) oral GCN2 activator, NXP800, for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. The ODD could...

August 30, 2024

Developments

Ventyx announces CFO departure and launches search for successor

Ventyx Biosciences (NASDAQ:VTYX) announced the departure of Martin Auster, M.D., as CFO, effective August 30, 2024, and has initiated a search for his successor. The company’s SVP of finance, Ron Gonzales, CPA, MBA, has...

August 30, 2024

Developments

Medigene secures patents advancing TCR-guided therapies

Medigene AG (FSE:MDG1) has announced that patents have been granted for its proprietary JOVI and iM-TCR technologies, enhancing the company’s End-to-End (E2E) platform of TCR-guided therapies for the treatment of cancer...

August 29, 2024

Developments

Gain reports positive topline results from Phase 1 trial of therapy for Parkinson’s

Gain Therapeutics (NASDAQ:GANX) has announced positive results from its Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson’s...

August 29, 2024

Developments

LIXTE and NKI dose first patient with LB100 in colorectal cancer study supported by Roche

LIXTE Biotechnology (NASDAQ:LIXT) has announced that, in collaboration with the Netherlands Cancer Institute (NKI), the first patient has been dosed in a new clinical trial of LUXTE’s lead compound, LB-100, for the...

August 26, 2024

Developments

Emergent donates 50,000 smallpox vaccine doses in response to WHO’s mpox declaration

Emergent BioSolutions (NYSE:EBS) announced its pledge to donate 50,000 doses of its ACAM2000 smallpox vaccine through Direct Relief in response to WHO’s declaration that the upsurge of mpox in the Democratic Republic of...

August 20, 2024

Developments

Tonix enrolls first patient in Phase 2 study of TX1300 for acute cocaine intoxication

Tonix Pharmaceuticals (NASDAQ:TNXP) announced the first patient dosing in its Phase 2 trial of the recombinant enzyme TNX-1300 for treating life-threatening cocaine intoxication in patients presenting to the emergency...

August 20, 2024

Developments

First participant dosed in Monte Rosa’s Phase 1 study of MRT-6160 for autoimmune disease

Monte Rosa Therapeutics (NASDAQ:GLUE) announced that the first participant has been dosed in its Phase 1 healthy volunteer study evaluating MRT-6160, a VAV1-directed MGB being developed for systemic and neurological...

August 19, 2024

Developments

Optimi Health announces export of first MDMA capsules for PTSD to Australia

Optimi Health (CSE:OPTI; OTCQX:OPTHF; FSE:8BN) reports completion of its inaugural export of GMP-validated, 3,4-methylenedioxymethamphetamine (MDMA) capsules to Australia for the treatment of patients with post...

August 16, 2024

Category - Developments

Subscribe